The rationale is as follows: if the deletion of SLC6A19 protects against obesity/metabolic syndrome and improves glycemic control, a similar metabolic outcome could be achieved with pharmacological inhibition of the transporter. Here, SLC6A19 is linked to metabolic syndrome.